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ArrhythmiasAbstract Background: During on-pump coronary artery bypass grafting (CABG) surgery, the
incidence of reperfusion ventricular ﬁbrillation (VF) is high and post-bypass ventricular arrhyth-
mias are common. Both reperfusion VF and ventricular arrhythmias can cause additional myocar-
dial injury to the already ischemic myocardium. This trial aimed to test the assumption that
continuous combined magnesium and lidocaine infusion would be efﬁcient and long lasting for
the prevention of post-myocardial vascularization ventricular arrhythmias including VF.
Methods: Eighty ASA III patients, who were candidates for CABG surgery, were randomly
assigned into two groups: Group I (control group, n= 40) and Group II (Group ML, n= 40).
After endotracheal intubation, patients of control group were infused with plain normal saline in
a volume equivalent to study drugs’ mixture volume. Patients of Group ML were infused with mag-
nesium–lidocaine mixture to achieve a bolus of magnesium sulfate 2 g and lidocaine 100 mg fol-
lowed by continuous infusion of Mg sulfate 500 mg/h and lidocaine 1 mg/min. The initial cardiac
rhythm after aortic cross clamp (ACC) release and the occurrence of post-CPB signiﬁcant ventric-
420 A.M.a.b. Elnakera, T.S.M. Alawadyular arrhythmias were recorded.
Results: The incidences of reperfusion VF and post-CPB ventricular arrhythmias in Group ML
were signiﬁcantly lower than that in control group (22.5% vs. 72.5%) (P< 0.001) and (7.5% vs.
25%) (P< 0.05), respectively. However, in Group ML, this beneﬁcial effect was associated with
higher incidence of sinus bradycardia (72.5% vs. 17.5%) and hence pacing needs (22.5% vs.
0.0%) when compared with control group.
Conclusion: Our study concluded that, during on-pump CABG surgery, the combined administra-
tion of magnesium and lidocaine as a bolus dose starting after intubation followed by continuous
infusion reduced the incidence of reperfusion VF by 62% and post-CPB ventricular arrhythmias by
70% on expense of increased the incidence of sinus bradycardia and pacing.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license.1. Introduction
Reperfusion ventricular ﬁbrillation (VF) occurs after removal
of aortic cross clamp (ACC) during on-pump coronary artery
bypass surgery (CABG) in a very high incidence (74–94%).
Reperfusion VF aggravates the myocardial damage and elec-
trical deﬁbrillation may cause additional injury for the already
ischemic myocardium [1–5]. Also, ventricular arrhythmias are
common during and after CABG with reported incidence of
34% [6]. Fortunately, fatal ventricular arrhythmias have a very
low incidence (0.41–1.4%), but if an episode of either sustained
ventricular tachycardia (VT) or VF occurs, the patient will be-
come at high risk of recurrence and poor cardiac outcome. So
prevention of both reperfusion VF and post-CPB ventricular
arrhythmias is a crucial part of effective myocardial protection
during CABG surgery [4,7,8].
Various interventions have been taken to prevent either
reperfusion VF or ventricular arrhythmias after cardiopulmo-
nary bypass (CPB) [1–10]. Some evidence has been developed
that there is high risk of magnesium (Mg) depletion during
CABG surgery with CPB. This hypomagnesaemia precipitates
both cardiac arrhythmias and/or vasoconstriction of either cor-
onary arteries or the used mammary artery graft which in turn
aggravates the arrhythmias [6,9,11,12]. SoMg supplementation
can stabilize the myocardial cell membrane and provide some
cardio protective effect against ventricular arrhythmias [6,11].
Another approach to prevent the occurrence of VF or ven-
tricular arrhythmias during CABG is the use of lidocaine
which is a local anesthetic and antiarrhythmic agent. Prophy-
lactic lidocaine reduced the incidence of reperfusion VF and
deﬁbrillation demand during CABG surgery [1–3].
So the aim of this prospective double blinded randomized
trial is to test the assumption that combined Mg and lidocaine
administration before ACC application in bolus doses followed
by continuous infusions till the end of surgery would be efﬁcient
and long lasting for the prevention of post-myocardial vascular-
ization ventricular arrhythmias including VF. The primary end
points were the incidence, refractoriness of reperfusion VF, and
the frequency of direct current (DC) counter shocks needed for
deﬁbrillation. The secondary end points were the incidence and
type of post-CPB ventricular arrhythmias till the end of surgery.2. Patients and methods
The study was conducted at Zagazig university hospital from
March 2010 to October 2011 after approval of local ethics com-mittee and obtaining patients’ informed consent. The study in-
cluded 80 ASA III patients, aged 40–70 years old, undergoing
elective CABG surgery using CPB. Exclusion criteria included
emergency operations, bradycardia (HR< 50/min), any preop-
erative cardiac rhythm other than sinus rhythm, preoperative
antiarrhythmic drug usage other than b blockers, concomitant
valvular lesion, compromised left ventricular function
(EF < 50%), either acute or chronic renal failure (serum creat-
inine<2 mg/dl), known allergy to any of the studymedications,
and inability to complete the study either due to intra-aortic bal-
loon pump counter pulsation (IABP) use or intraoperative
death.
All patients were premedicated using intravenous midazo-
lam (0.05–0.1 mg/kg) before admission to the operating room
(OR). On arrival to the OR, basic monitoring started with
continuous ﬁve leads ECG monitoring, pulse oximetry, and
non-invasive blood pressure monitoring (Siemens SC 7000).
After arterial line insertion and establishment of continuous
invasive blood pressure monitoring, all patients were induced
using sodium thiopental (2–3 mg/kg) and fentanyl (5–8 ug/
kg). Endotracheal intubation was facilitated with pancuroni-
um (0.15 mg/kg) and then controlled lung ventilation (volume
mode) was started using 100% oxygen. Central venous line
was inserted and then central venous pressure (CVP), esoph-
ageal temperature and urine output (UOP) were continuously
monitored. Hypotension, deﬁned as a drop of MAP< 20%
of baseline, was treated with ﬂuids and vasopressors. Brady-
cardia deﬁned as HR< 50/min was treated with atropine,
adrenaline, and/or pacing in addition to stopping the study’s
drug infusion. Tachycardia deﬁned as HR> 100/min was
treated with increasing the anesthetic depth, infusing ﬂuid bo-
lus, and optimizing acid–base and electrolytes. Hypertension
deﬁned as an increase in MAP< 20% of baseline was treated
with increasing anesthetic depth and dilators. Anesthesia was
maintained using isoﬂurane 1.2–2% in oxygen–air mixture
(replaced on CPB by propofol infusion) and intravenous infu-
sion of fentanyl (5 ug/kg/h) and midazolam (0.05 mg/kg/h).
Pancuronium (0.05 mg/kg) was given as intermittent time
based boluses. Using randomization software generator, pa-
tients were randomly assigned to one of the two studied
groups (40 patients each). After endotracheal intubation, pa-
tients of control group were infused with plain normal saline
in a volume equivalent to study drugs’ mixture volume. Pa-
tients of group II [group Mg–lidocaine (ML)] were infused
with a mixture of Mg sulfate (2 g) and lidocaine (100 mg) di-
luted in 50 ml normal saline 0.9% over 20 min followed by
continuous infusion of 20 ml/h normal saline solution con-
Continuous Infusion of Magnesium-Lidocaine Mixture 421taining Mg sulfate (25 mg/ml) and lidocaine (3 mg/ml) to
achieve 500 mg/h. of Mg sulfate and 1 mg/min of lidocaine
until skin closure. The infusions were running as long as
UOP was accepted (<1 ml/kg/h). The anesthetist and sur-
geon who managed the patients were unaware of the treat-
ment group. Standard CPB was established using systemic
cooling down to 28–30 C. All patients were perfused by
stocker roller pump at ﬂow rate 2–2.5 L/min/m2. The MAP
was maintained at 70–80 mmHg. After ACC application, top-
ical cooling was applied and ante grade cold crystalloid car-
dioplegic solution was infused through the aortic root with
induction dose of 20 ml/kg. Cardioplegic solution mainte-
nance dose was 10 ml/kg every 20–25 min. The constituents
per 1000 ml saline 0.9% of cardioplegic solution were potas-
sium (20 mEq), Mg (12 mEq), calcium (0.7 mEq), NaHCO3
(20 mEq), and lidocaine (100 mg). In all patients, the left
internal mammary artery was anastomozed as a bypass con-
duit to the left anterior descending artery. For free grafts
after completion of the distal anastomosis, the aorta was de-
clamped and the proximal anastomoses were performed with
aortic side occlusion clamp. Before the aorta was declamped,
the blood is rewarmed to 32 C, ventricular deaireation was
performed, and blood chemistry was optimized with serum
K+ maintained at 5–5.5 mEq/L. The initial cardiac rhythm
after removal of ACC was analyzed. If the rhythm is VF,
electrical deﬁbrillation using 30–50 J internal shocks was per-
formed. If VF was refractory, amiodarone (300 mg) was used
and this was accompanied with optimization of MAP, correc-
tion of blood chemistry parameters, and prompt concern
about coronary blood ﬂow impairment (S–T segment
changes). If myocardial ischemia was suspected, the surgeon
revised the performed grafts and nitroglycerine was added
when MAP allowed. Ventricular arrhythmias were treated
with serum electrolytes’ correction, amiodarone, and/or elec-
trical cardioversion as appropriate. If the rhythm was AF,
synchronized cardioversion using 10–20 J was tried. Electrical
pacing was indicated for high degree atrio-ventricular conduc-
tion (A-V) block or sinus bradycardia HR< 60 mmHg.
Weaning from CPB was started when the following criteria
were met: ﬁnishing of bypass procedures, a manageable level
of surgical bleeding, complete rewarming to 36.5 C, and sta-
ble cardiac rate and rhythm. Fluid/blood boluses, inotropes,
vasodilators, and/or vasopressors were used as indicated for
hemodynamic stability and were recorded. Hemodynamic,
ventilation, and blood chemistry parameters were optimized
throughout the post-bypass period. In cardiac surgical ICU,
all patients were ventilated and monitored till extubation cri-
teria were met.
Preoperative collected patients’ data included age, sex,
weight, Euro SCORE II, b blockers, and diuretic usage, which
coronary vessel was occluded, and serumMg level. Intraopera-
tive data included baseline patient’s MAP, HR, CPB and ACC
times, operative time (starting from anesthetic induction until
skin closure), and the number of grafts done.
After release of ACC, the time to appearance of the ﬁrst car-
diac electrical activity and the initial cardiac rhythm were regis-
tered.Data recorded included the occurrence of refractoryVFas
well as the number of DC shocks needed for deﬁbrillation and
the use of further antiarrhythmic drugs, and also, the presence
of sinus bradycardia (HR< 60/min) or A-V block was regis-
tered. After weaning from CPB, the needs for inotropes and/or
vasoactive drugs as well as the need for electrical pacing wereconsidered for analysis. If post-CPB ventricular arrhythmias oc-
curred, their type and therapeutics neededwere also recorded. In
this study, signiﬁcant ventricular arrhythmias included multiple
(<5 beats/min), multifocal, or bigeminal premature ventricular
contractions (PVCs), non-sustained ventricular tachycardia
(6 beats – 29 s), sustainedVT (>30 s duration or requiring inter-
vention for termination), andVF [7,8,13]. Postoperative data in-
cluded serum Mg level (Cobas Integra 400+ by Roche
Diagnostics, Switzerland) on ICU admission and time to tra-
cheal extubation (h) as measured from the end of CPB.
In a small pilot study with conﬁdence interval 95% and
power of the study 80%, the overall reduction in ventricular
arrhythmias during CABG was 33%; so the sample size was
estimated to be 40 patients in each group.
Statistical analysis: Qualitative variables were expressed as
number and percentage and comparison between two groups
was carried out using Chi-square test and Fisher Exact test
when expected cells were less than 5. Quantitative variables
were expressed as mean and standard deviation when data
were parametric and comparison between groups was done
by T test. Nonparametric data were expressed by median
and compared by Mann–Whitney U test. P value less than
0.05 was considered signiﬁcant.3. Results
Therewere no signiﬁcant differences between patients of the two
groups as regard age, sex, body weight, Euro SCORE, diuretics,
or b blockers usage. The patients did not differ either as regard
basal hemodynamic proﬁle, number of affected coronary arter-
ies (either planned for vascularization or already vascularized),
or CPB, ACC, operative, and extubation times. All patients in
both groups had left anterior descending artery lesions and did
not differ statistically as regard the other affected coronary
arteries (Tables 1 and 2).
After the release of ACC, the incidence of reperfusion VF in
Group ML was highly signiﬁcantly lower than that in control
group (22.5% vs. 72.5%) (P< 0.001), but the incidence of sinus
bradycardia and the associated pacing needs were signiﬁcantly
higher in group ML compared with control group (P< 0.001
and 0.05, respectively). However, no patient in both groups
was presented by either atrial ﬁbrillation or high degree of heart
block after the release of ACC (Fig. 1).
As regard the time to appearance of electrical activity after
the ACC release, it was highly prolonged in group ML (about
9 min) compared with control group (about 3 min)
(P< 0.001). The number of DCs needed for deﬁbrillation
was highly signiﬁcantly lower in group ML compared with
control group (P< 0.001) (Table 3).
There was no signiﬁcant difference between patients of both
groups in their needs for either vasopressors or inotropic sup-
port after CPB (Table 4).
The number of patients with post-CPB ventricular arrhyth-
mias was signiﬁcantly lower in group ML compared with con-
trol group. The difference was mainly due to the signiﬁcantly
lower incidence of multiple PVCs in the control one. All cases
of post-CPB ventricular arrhythmias responded to increased
anesthetic depth and optimization of potassium and acid base,
but the two cases who develop sustained VT and VF (both in
control group) mandated electrical cardio version/deﬁbrilla-
tion and amiodarone infusion (Fig. 2).
Table 1 Patients’ characteristics, basal hemodynamics, operative times, and number of the affected coronary arteries (either planned
for vascularization or already vascularized).
Control (N. 40) Group ML (N. 40) Test of signiﬁcance P value
Age (Ys) 58.05 ± 10.89 57.10 ± 10.08 0.41 0.68
Body weight (kg) 96.32 ± 14.69 93.0 ± 13.77 1.04 0.3
Euro score 1.07 ± 0.37 1.06 ± 0.4 0.14 0.88
MAP0 (mmHg) 103.7 ± 8.13 103.2 ± 8.83 0.26 0.79
HR0 (beat/min) 73.87 ± 6.55 75.05 ± 6.43 0.81 0.42
CPB time (min) 111.75 ± 38.42 110.62 ± 34.79 0.14 0.89
ACC time (min) 85.12 ± 27.9 84.25 ± 29.1 0.141 0.89
Operative time (min) 267.5 ± 50.56 271.87 ± 45.92 0.41 0.68
Extubation time (h) 8.4 ± 3.67 9.1 ± 3.74 0.84 0.4
Number of grafts planned to be done 1.95 ± 0.68 2.05 ± 0.68 0.65 0.51
Number of grafts already done 1.7 ± 0.57 1.75 ± 0.64 0.37 0.71
MAP0: baseline mean arterial pressure, HR0: baseline heart rate, CPB: cardiopulmonary bypass, ACC: aortic cross clamp.
Group ML: magnesium–lidocaine group. Data are expressed as mean ± SD. No signiﬁcant differences between the studied groups.
Table 2 Patients’ sex, preoperative drug therapy, and type of diseased coronary arteries.
Control (N. 40) Group ML (N. 40) Test of signiﬁcance P value
N. % N. %
Sex female 16 40 13 32.5 v2 = 0.49 0.48
Male 24 60 27 67.5
Patients on diuretics 9 22.5 7 17.5 v2 = 0.31 0.57
Patients on B-blockers 34 85 32 80 v2 = 0.34 0.55
Right coronary artery (RC) 22 55% 21 52.5% 0.05 0.82
Circumﬂex artery 10 25% 13 32.5% 0.55 0.45
Oblique marginal artery (OM) 7 17.5% 6 15% 0.09 0.76
Group ML: magnesium–lidocaine group. Data are expressed as number and percentage. No signiﬁcant differences between the studied groups.
Figure 1 Initial cardiac rhythm after aortic cross clamp (ACC)
release: Percentage of different types of ventricular arrhythmia in
both groups. Group ML: magnesium–lidocaine group. VF:
ventricular ﬁbrillation. ACC: aortic cross clamp. Data were
expressed as percentage. *Signiﬁcant difference (P< 0.05).
**Highly signiﬁcant difference (P< 0.001).
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groups. However, postoperative Mg level was highly increased
in group ML, and in contrast, it was highly reduced in the con-
trol group when compared with basal levels (Fig. 3).4. Discussion
The current study revealed that the continuous infusion of
magnesium–lidocaine (ML) mixture resulted in a delay in the
reappearance of spontaneous electrical activity and reduction
in the incidence of both spontaneous VF after release of
ACC and post-CPB ventricular arrhythmias compared with
control group during CABG surgery. The combination also
lowered the number of DC shocks needed for deﬁbrillation.
These effects were at the expense of the increased incidence
of sinus bradycardia and pacing needs with no additional need
for inotropes or vasopressors. Postoperative serum Mg level
was seen to be lower in non-Mg treated patients.
Multiple randomized controlled trials (RCTs) demon-
strated the ability of Mg either as a bolus or as a continuous
infusion to reduce postoperative arrhythmias after open heart
surgery by different percentages [8,9,14–17]. However, other
studies found no signiﬁcant beneﬁcial effect of using Mg, either
before or during CPB on the incidence of either reperfusion
VF or post-CPB ventricular arrhythmias during CABG sur-
gery [6,18].
The use of lidocaine in multiple RCTs, either as IV bolus
only or IV bolus followed by maintenance infusion before
ACC release, showed conﬂicting results. In some of the trials,
lidocaine can reduce the incidence of reperfusion VF by up to
84% [1–4,19]; in others, no reduction in the incidence of VF
was noticed [20,21].
Table 3 Time to appearance of electrical activity after the release of aortic cross clamp and the number of DCs needed for electrical
deﬁbrillation.
Control
(N. 40)
Group ML
(N. 40)
Z value P value
Time to appearance of electrical activity after the release of
aortic cross clamp (min)
3 (0.5–4) 9 (4–12)** 7.67 < 0.001
The number of DCs needed for electrical cardio version 2 (0–12) 0 (0–8)** 4.15 < 0.001
DCs: direct current shocks.
Group ML: magnesium–lidocaine group. Data are expressed as median and range.
** Highly signiﬁcant difference (P< 0.001).
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Figure 2 Percentage of different types of post-CPB ventricular
arrhythmia in both groups. Group ML: magnesium–lidocaine
group. CPB: cardiopulmonary bypass. VF: ventricular ﬁbrillation.
VT: ventricular tachycardia. PVC’s: premature ventricular con-
tractions. Data are expressed as percentage. *Signiﬁcant difference
(P< 0.05).
Figure 3 pre- and postoperative serum Mg level (mg/dl) in both
groups. Group ML: magnesium–lidocaine group. Mg: magne-
sium. Data are expressed as mean ± SD. **Highly signiﬁcant
difference from control group (P< 0.001). Highly signiﬁcant
difference from baseline (P< 0.001).
Table 4 The need for vasopressors and inotropic support
after CPB.
Control (N. 40) Group ML (N. 40) v2 P value
N. % N. %
The need for
inotropic support
32 80 35 88 0.83 0.36
The need for
vasopressors
8 20 10 25 0.29 0.59
Group ML: magnesium–lidocaine group. Data are expressed as
number and percentage. No signiﬁcant differences between the
studied groups.
Continuous Infusion of Magnesium-Lidocaine Mixture 423In this study, we tried to beneﬁt from the potential synergis-
tic effect of using both Mg and lidocaine in safe doses to avoid
their side effects. As Mg administration before, during surgi-
cally induced myocardial ischemia, and at the time of myocar-
dial reperfusion appears to improve post-ischemic myocardial
mechanical recovery but if given after myocardial reperfusion
has begun, it does not produce this beneﬁcial effect [14]. We
use the mixture as bolus (Mg sulfate 2 g and lidocaine
100 mg) before CPB followed by infusion of Mg sulfate(500 mg/h) and lidocaine (1 mg/min) to allow long lasting pro-
phylactic effect on both reperfusion VF and post-CPB ventric-
ular arrhythmias.
Reappearance of spontaneous electrical activity, after the
release of ACC, was delayed on using ML mixture in our
study. This was considered beneﬁcial to allow better perfusion
to the myocardium without increase in myocardial oxygen
consumption. A similar effect was revealed by Capsi and asso-
ciates on the use of 4 g of Mg sulfate on the prebypass period
[15].
Our results showed a reduction in the incidence of reperfu-
sion VF by 62% in ML group. This is in agreement with Vaz-
iriand associates who revealed a reduction of 72.7% or 38.9%
in the incidence of reperfusion VF on using an IV bolus dose of
Mg (30 mg/kg) or lidocaine (1.5 mg/kg) respectively before
ACC release [10]. Similar ﬁndings were revealed on using lido-
caine 100 mg, 200 mg or 2 mg/kg before ACC release [1–4].
The number of patients, who suffered refractory VF after
ACC release in the present study, was lower in group ML
but the difference did not reach statistical signiﬁcance. How-
ever, the average number of DC shocks, needed for deﬁbrilla-
tion, was statistically lower in group ML compared with
control one and the difference reached high signiﬁcance. Our
ﬁnding was in agreement with Praeger and associates who re-
vealed that lidocaine, given before ACC release, was associated
with lower number of DC shocks per patient with sustained
424 A.M.a.b. Elnakera, T.S.M. Alawadyﬁbrillation [3]. In contrast, Hecker and associates showed no
signiﬁcant beneﬁcial effect of Mg on the incidence of reperfu-
sion VF, when used either before (0.375 mEq/kg) or during
CPB (25 mEq/kg), and found that the number and energy of
DC shocks, needed for deﬁbrillation, were greatest among
the patients who received Mg before CPB [18]. The difference
of our ﬁndings from that revealed by Hecker and associates
may be due to different Mg infusion regimen used or the com-
bined use of Mg and lidocaine in the current study.
Signiﬁcant reduction in the incidence of postoperative ven-
tricular arrhythmias was demonstrated by King and associates
on using lidocaine (100 mg IV bolus followed by 2 mg/min
infusion) and by England and associates on using Mg chloride
(2 g IV bolus) after CPB [9,22]. In contrast, Juneja and associ-
ates showed that lidocaine administration cannot produce sig-
niﬁcant beneﬁt for prophylaxis against ventricular arrhythmias
in patients with poor left ventricular function [20] and also Ha-
mid and associates failed to demonstrate signiﬁcant beneﬁcial
effect on the prevention of ventricular arrhythmias after CPB
when using 2 g of Mg sulfate after intubation [6]. Our results
showed a 70% reduction in the incidence of post-CPB ventric-
ular arrhythmias in group ML; this may be due to the use of
Mg–lidocaine combination or the different study’s patient
population.
The current study supported the myocardial protective ben-
eﬁt of the Mg–lidocaine combination that can be explained by
their mechanisms of action. Mg acts as a natural calcium chan-
nel blocker which can also block the formation of oxygen free
radicals [14] and may also play a role as a free radical scaven-
ger [11]. Mg, as a cofactor for many cellular ATPases, can pre-
vent the intracellular sodium load and has a central role in
restoration of oxidative metabolism and regulation of myocar-
dial muscle function and tone [14]. Lidocaine also is an antiar-
rhythmic drug that acts via inhibition of Na channels, so it can
increase the threshold for VF and preserve the energy away
from electromechanical activity allowing better recovery of
the heart. Lidocaine also can block the slow calcium channels
[2,23–25].
In the current study, the reduction in the incidence of reper-
fusion VF was associated with increased incidence of sinus
bradycardia and pacing needs in ML group. This ﬁnding was
in agreement with that by Wistbacka and associates on using
high dose of Mg chloride (>4 g prebypass and >12 g until
the end of 1st postoperative day) [26]. Our patients who re-
quired pacing were weaned from it by the end of the 1st post-
operative day. Tchervenkov and associates demonstrated a
highly signiﬁcant reduction in the incidence of spontaneous
VF after ACC release, on using lidocaine (500 mg/L) contain-
ing crystalloid cardioplegia, at the expense of increased inci-
dence of high degree A-V block [27]. In our study, no
patient suffered high degree A-V block, and this may be due
to the lower and continuous dose of lidocaine infusion and this
in agreement with many RCTs which showed the beneﬁcial ef-
fect of lidocaine (given as bolus either followed by continuous
infusion or not) to prevent reperfusion VF without signiﬁcant
A-V block [1–4,19]; also no patient in our study suffered bra-
dycardia <50/min that mandated stoppage of the study’s
drugs.
Hypotension is a possible side effect with Mg infusion [8];
however, in the present study, episodes of hypotension were
transient and rapidly responding to ﬂuid loading without sig-
niﬁcant increase in the need for inotropes or vasopressors inpatients of group ML compared with control one. This can
be explained that myocardial depressant effect of the Mg
was compensated by reduction in systemic and coronary vas-
cular resistance maintaining effective pumping function
[15,28]. The reduction in the rate of reperfusion VF may also
play an essential role in improvement of myocardial perfor-
mance and cardiac output [4,9,23].
Post-cardiac surgery reduction in serum Mg, in non-Mg
treated patients was revealed in many studies [6,16]. Postoper-
ative serum Mg level, in current study, was signiﬁcantly re-
duced in non-Mg treated patients. Although postoperative
serum Mg remained within normal limit, intracellular hypo-
magnesaemia cannot be excluded [14].
Limitations of the current study were the small patients’
number and the limited study period as postoperative course
was not included. Further studies are needed to investigate
the efﬁcacy of this prophylactic approach and to relate reduc-
tion in both reperfusion VF and post-CPB arrhythmias to the
cardiac morbidity and mortality of these patients.
This study concluded that, during on-pump CABG sur-
gery, the combined administration of Mg and lidocaine as
a bolus dose starting after intubation followed by continu-
ous infusion reduced the incidence of reperfusion VF by
62% and post-CPB ventricular arrhythmias by 70% at the
expense of increasing the incidence of sinus bradycardia
and hence pacing needs without additional inotropic or
vasopressor requirements.References
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